The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
Open accessAbstract
1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with a unique biological profile giving potent, selective anti-human immunodeficiency virus (HIV) activity. 1592U89 was selected after evaluation of a wide variety of analogs containing a cyclopentene substitution for the 2'-deoxyriboside of natural deoxynucleosides, optimizing in vitro anti-HIV potency, oral bioavailability, and central nervous system (CNS) penetration. 1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT). 1592U89 showed minimal cross-resistance (approximately twofold) with AZT and other approved HIV reverse transcriptase (RT) inhibitors. 1592U89 was synergistic in combination with AZT, the nonnucleoside RT inhibitor nevirapine, and the protease inhibitor 141W94 in MT4 cells against HIV-1 (IIIB). 1592U89 was anabolized intracellularly to its 5'-monophosphate in CD4+ CEM cells and in PBLs, but the di- and triphosphates of 1592U89 were not detected. The only triphosphate found in cells incubated with 1592U89 was that of the guanine analog (-)-carbovir (CBV). However, the in vivo pharmacokinetic, distribution, and toxicological profiles of 1592U89 were distinct from and improved over those of CBV, probably because CBV itself was not appreciably formed from 1592U89 in cells or animals (<2%). The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM). 1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines. 1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT. Having demonstrated an excellent preclinical profile, 1592U89 has progressed to clinical evaluation in HIV-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase
St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., & Larder, B. A. (1991) · Science · doi:10.1126/science.1716788 · Cited by 679
Self-citationTisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Self-citationFischl, M. A., Richman, D. D., Hansen, N., Collier, A. C., Carey, J. T., Para, M. F., Hardy, W. D., Dolin, R., Powderly, W. G., Allan, J. D., et al. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-10-727 · Cited by 601
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis
Martin, J. L., Brown, C. E., Matthews-Davis, N., & Reardon, J. E. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.12.2743 · Cited by 343
Self-citationGarrett, C., & Santi, D. V. (1979) · Analytical Biochemistry · doi:10.1016/s0003-2697(79)80005-6 · Cited by 267
Vince, R., Hua, M., Brownell, J., Daluge, S., Lee, F., Shannon, W. M., Lavelle, G. C., Qualls, J., Weislow, O. S., Kiser, R., et al. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80950-1 · Cited by 232
Self-citationUnique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
Faletto, M. B., Miller, W. H., Garvey, E. P., St Clair, M. H., Daluge, S. M., & Good, S. S. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1099 · Cited by 224
Self-citationTisdale, M., Alnadaf, T., & Cousens, D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1094 · Cited by 223
Self-citationZimmerman, T. P., Mahony, W. B., & Prus, K. L. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45638-4 · Cited by 222
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex
Yarchoan, R., Pluda, J. M., Thomas, R. V., Mitsuya, H., Brouwers, P., Wyvill, K. M., Broder, S., Hartman, N., & Johns, D. G. (1990) · The Lancet · doi:10.1016/0140-6736(90)92085-v · Cited by 215
Sherman, P. A., & Fyfe, J. A. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90420-x · Cited by 211
Ho, H. T., & Hitchcock, M. J. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.6.844 · Cited by 195
Reardon, J. E. (1992) · Biochemistry · doi:10.1021/bi00133a013 · Cited by 147
Self-citationParker, W. B., White, E. L., Shaddix, S. C., Ross, L. J., Buckheit, R. W., Germany, J., Secrist, J. A. I., Vince, R., & Shannon, W. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52360-7 · Cited by 132
Reardon, J. E., & Miller, W. H. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30504-5 · Cited by 111
Self-citationKavlick, M. F., Shirasaka, T., Kojima, E., Pluda, J. M., Hui, F. K., Yarchoan, R., & Mitsuya, H. (1995) · Antiviral Research · doi:10.1016/0166-3542(95)00044-m · Cited by 83
Dornsife, R. E., Clair, M. H. S., Huang, A. T., Panella, T. J., Koszalka, G. W., Burns, C. L., & Averett, D. R. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.2.322 · Cited by 80
Self-citationMutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine
Remington, K. M., Chesebro, B. W., Wehrly, K., Pedersen, N. C., & North, T. W. (1991) · Journal of Virology · doi:10.1128/jvi.65.1.308-312.1991 · Cited by 79
Daluge, S. M., Purifoy, D. J. M., Savina, P. M., Clair, M. H. S., Parry, N. R., Dev, I. K., Novak, P., AYERS, K. M., Reardon, J. E., & Roberts, G. B. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1590 · Cited by 60
Self-citationDose-Related Activity Of Stavudine In Patients Infected With Human Immunodeficiency Virus
Petersen, E. A., Ramirez-Ronda, C. H., Hardy, W. D., Schwartz, R., Sacks, H. S., Follansbee, S., Peterson, D. M., Cross, A. P., Anderson, R. E., & Dunkle, L. M. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_2.s131 · Cited by 55
Safety and tolerance of dideoxycytidine as a single agent
Merigan, T. C., & Skowron, G. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90415-a · Cited by 48
Jansen, R. W., Johnson, L. C., & Averett, D. R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.441 · Cited by 46
Self-citationReardon, J. E., Furfine, E. S., & Cheng, N. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)92818-8 · Cited by 42
Self-citationSpector, T., Jones, T., & Beacham, L. M. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90010-2 · Cited by 37
Anti-HIV compound assessment by two novel high capacity assays
Averett, D. R. (1989) · Journal of Virological Methods · doi:10.1016/0166-0934(89)90159-6 · Cited by 35
Self-citationDu, D., Volpe, D. A., Grieshaber, C. K., & Murphy, M. J. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb04555.x · Cited by 25
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
Mehellou, Y., & De Clercq, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900492g · Cited by 368
Metadata
- Authors
- Daluge, S. M., Good, S. S., Faletto, M. B., Miller, W. H., St Clair, M. H., Boone, L. R., Tisdale, M., Parry, N. R., Reardon, J. E., Dornsife, R. E., Averett, D. R., & Krenitsky, T. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-05
- Volume
- 41
- Issue
- 5
- Pages
- 1082-1093
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2162705413
- Cited by
- 384
- References
- 28
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.